Biologics/Immunotherapy News

Nearly 3 years into the pandemic, COVID-19 continues to dominate headlines and research labs as scientists explore therapies that mitigate the impact of the virus, particularly among patients with asthma and allergy.

LOUISVILLE, Ky. — Dupilumab improved symptoms among patients with chronic rhinosinusitis with nasal polyps regardless of baseline severity of smell loss, according to study results.

LOUISVILLE, Ky. — Familiarity with oral immunotherapy as treatment for food allergy significantly varies by race and ethnicity, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

LOUISVILLE, Ky. — Patients assigned omalizumab for moderate to severe chronic spontaneous urticaria experienced superior time to clinically meaningful response compared with those on placebo, according to study results.

LOUISVILLE, Ky. — Multi-allergen oral immunotherapy may reduce treatment time overall but also led to significant increases in epinephrine use compared with single-allergen oral immunotherapy, according to study results.

LOUISVILLE, Ky. — Most patients undergoing oral immunotherapy milestone challenges passed with few requiring epinephrine, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

In this Healio video exclusive, Nicola A. Hanania, MD, MS, highlights presentations from the CHEST Annual Meeting discussing biologic choice — particularly tezepelumab — in patients with severe asthma.

LOUISVILLE, Ky. — Communication can improve compliance and outcomes among teenagers on peanut oral immunotherapy, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

LOUISVILLE, Ky. — Dupilumab improved chronic spontaneous urticaria among patients whose disease did not respond to H1 antihistamines, according to a presentation here.

LOUISVILLE, Ky. — The use of a peanut immunotherapy patch for 12 months appeared to reduce reaction severity while increasing eliciting dose among toddlers, according to results from the phase 3 EPITOPE study.